Kotaro Shide
A5040331469- Myeloproliferative Neoplasms: Diagnosis and Treatment
- T-cell and Retrovirus Studies
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Kruppel-like factors research
- Animal Disease Management and Epidemiology
- Eosinophilic Disorders and Syndromes
- Vector-Borne Animal Diseases
- Cytokine Signaling Pathways and Interactions
- Lymphoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Platelet Disorders and Treatments
- Plant Virus Research Studies
- Viral-associated cancers and disorders
- Chronic Lymphocytic Leukemia Research
- Liver Disease Diagnosis and Treatment
- Galectins and Cancer Biology
- Viral Infections and Immunology Research
- Insect Pheromone Research and Control
- Viral Infectious Diseases and Gene Expression in Insects
- Hemiptera Insect Studies
- Immune Response and Inflammation
- Phagocytosis and Immune Regulation
- Cancer Genomics and Diagnostics
- interferon and immune responses
University of Miyazaki
2016-2025
Diabetes Australia
2022-2023
Kyushu University
2003-2007
Kyushu University Hospital
2005-2006
Mutations of calreticulin (CALR) are detected in 25–30% patients with essential thrombocythemia (ET) or primary myelofibrosis and cause frameshifts that result proteins a novel C-terminal. We demonstrate CALR mutations activated signal transducer activator transcription 5 (STAT5) 293T cells the presence thrombopoietin receptor (MPL). Human megakaryocytic CMK11-5 erythroleukemic F-36P-MPL knocked-in showed increased growth acquisition cytokine-independent growth, respectively, accompanied by...
Abstract Pulmonary hypertension (PH) is a progressive cardiopulmonary disease characterized by pulmonary arterial remodeling. Clonal somatic mutations including JAK2 V617F, the most frequent driver mutation among myeloproliferative neoplasms, have recently been identified in healthy individuals without hematological disorders. Here, we reveal that clonal hematopoiesis with JAK2V617F exacerbates PH and remodeling mice. JAK2V617F-expressing neutrophils specifically accumulate regions,...
Abstract Adult T-cell leukemia/lymphoma (ATL) is a peripheral malignancy with poor prognosis. We conducted retrospective study across six institutions in Miyazaki Prefecture, Japan, to assess the efficacy of tucidinostat patients relapsed/refractory ATL who had not undergone transplantation. Between October 2021 and July 2023, 24 aged 41 88 years (median, 73.4 years) prior therapies, including intensive chemotherapy (79.2%) mogamulizumab immunotherapy (79.2%), received tucidinostat....
Abstract Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by clonal myeloproliferation, progressive bone marrow (BM) fibrosis, splenomegaly, and anemia. BM fibrosis was previously thought to be reactive phenomenon induced mesenchymal stromal cells that are stimulated the overproduction of cytokines such as transforming growth factor (TGF)-β1. However, involvement neoplastic fibrocytes in recently reported. In this study, we showed vast majority collagen-...
Summary The acquired JAK2 V617F mutation is observed in the majority of patients with BCR‐ABL1 negative chronic myeloproliferative neoplasms (MPN). MPN displays myeloproliferation an elevated leucocyte alkaline phosphatase (LAP) activity, a neutrophil activation marker. We tried to separate downstream signalling stimulate and LAP activity. NB4, myeloid lineage cell line, was transduced Jak2 or wild‐type . found that mutation, but not enhanced expression NB4‐derived neutrophils proliferation...
Aberrant activation of Janus kinase 2 (JAK2) caused by somatic mutation JAK2 (JAK2V617F) or the thrombopoietin receptor (MPLW515L) plays an essential role in pathogenesis myeloproliferative neoplasms (MPNs), suggesting that inhibition aberrant would have a therapeutic benefit. Our novel inhibitor, NS-018, was highly active against with 50% (IC(50)) <1 n, and had 30-50-fold greater selectivity for over other JAK-family kinases, such as JAK1, JAK3 tyrosine 2. In addition to JAK2, NS-018...
The prognosis of aggressive adult T-cell leukemia/lymphoma (ATL) is poor, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) a curative treatment. In order to identify favorable prognostic patients after intensive chemotherapy, who therefore might not require upfront allo-HSCT, we aimed improve risk stratification ATL aged <70 years. clinical factors genetic mutations were incorporated into modeling for overall survival (OS). We generated the m7-ATLPI, clinicogenetic model...
Abstract Background Whether human T-lymphotropic virus type 1 (HTLV-1) carriers can develop sufficient humoral immunity after coronavirus disease 2019 (COVID-19) vaccination is unknown. Methods To investigate COVID-19 in HTLV-1 carriers, a multicenter, prospective observational cohort study was conducted at five institutions southwestern Japan, an endemic area for HTLV-1. and HTLV-1-negative controls were enrolled this from January to December 2022. During period, the third dose of vaccine...
Abstract Premalignant clonal expansion of human T-cell leukemia virus type-1 (HTLV-1)–infected cells occurs before viral carcinogenesis. Here we characterize premalignant and the multicellular ecosystem in HTLV-1 infection with without adult leukemia/lymphoma (ATL) by genome sequencing single-cell simultaneous transcriptome T/B-cell receptor surface protein analysis. We distinguish malignant phenotypes caused leukemogenesis dissect evolution different clinical behavior. Within...
A single somatic mutation, V617F, in Janus kinase 2 (JAK2) is one of the causes myeloproliferative neoplasms (MPNs), including primary myelofibrosis, and JAK2V617F mutant a therapeutic target MPN. However, inhibition wild-type (WT) JAK2 can decrease erythrocyte or platelet (PLT) count. Our selective inhibitor, NS-018, suppressed growth Ba/F3 cells harboring more strongly than that WT JAK2. The 4.3-fold selectivity NS-018 higher 1.0- to 2.9-fold seven existing inhibitors. also inhibited...